METTL3 Is Involved in the Development of Graves' Disease by Inducing SOCS mRNA m6A Modification.

Area of Science:

• Molecular Biology
• Epigenetics
• Immunology

Background:

• RNA epigenetic modifications regulate gene expression and cell differentiation.
• Suppressor of cytokine signaling (SOCS) family members are key genes involved in cellular processes.
• Graves' disease (GD) is an autoimmune disorder affecting the thyroid.

Purpose of the Study:

• To investigate the relationship between methyltransferase like 3 (METTL3)-induced mRNA methylation of SOCS family members and Graves' disease (GD).
• To explore the role of METTL3 in the pathogenesis of GD.

Main Methods:

• Microarray analysis of differentially expressed genes (DEGs) in GD tissues.
• Validation using CD4+ T cell microarrays and peripheral blood mononuclear cells (PBMCs).
• METTL3 knock-down experiments in RAW264.7 cells to assess target gene expression.

Main Results:

• METTL3 and SOCS molecules were aberrantly expressed in GD thyroid tissues and CD4+ T cells.
• Bioinformatic analysis identified SOCS family genes with multiple mRNA m6A modification sites.
• METTL3 knock-down led to increased expression of SOCS1, SOCS2, SOCS4, SOCS5, and SOCS6.

Conclusions:

• This study is the first to reveal the link between m6A modification and GD.
• METTL3 may contribute to GD development through mRNA m6A methylation of SOCS family members.
• METTL3-mediated SOCS regulation represents a potential therapeutic target for GD.